Mining Bugs for Drugs

Ross Youngs, CEO and founder of Biosortia Microbiomics, discusses the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.